Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Clinical and Basic Studies on Therapeutic Efficacy of Herbal Medicines against Mycobacterial Infections.

Tomioka H, Tatano Y, Shimizu T, Sano C.

Medicines (Basel). 2019 Jun 19;6(2). pii: E67. doi: 10.3390/medicines6020067. Review.

2.

Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1.

Hara Y, Torii R, Ueda S, Kurimoto E, Ueda E, Okura H, Tatano Y, Yagi H, Ohno Y, Tanaka T, Masuko K, Masuko T.

Cancer Sci. 2018 Oct;109(10):3171-3182. doi: 10.1111/cas.13755. Epub 2018 Aug 26.

3.

Identification of Novel Mycobacterial Inhibitors Against Mycobacterial Protein Kinase G.

Kanehiro Y, Tomioka H, Pieters J, Tatano Y, Kim H, Iizasa H, Yoshiyama H.

Front Microbiol. 2018 Jul 12;9:1517. doi: 10.3389/fmicb.2018.01517. eCollection 2018.

4.

Anti-Mycobacterium avium complex activity of clarithromycin, rifampin, rifabutin, and ethambutol in combination with adenosine 5'-triphosphate.

Tatano Y, Yamabe S, Sano C, Tomioka H.

Diagn Microbiol Infect Dis. 2017 Jul;88(3):241-246. doi: 10.1016/j.diagmicrobio.2017.04.012. Epub 2017 May 2.

PMID:
28511780
5.

Host-Directed Therapeutics against Mycobacterial Infections.

Tomioka H, Sano C, Tatano Y.

Curr Pharm Des. 2017;23(18):2644-2656. doi: 10.2174/1381612822666161202121550. Review.

PMID:
27908271
6.

Hypatulins A and B, Meroterpenes from Hypericum patulum.

Tanaka N, Yano Y, Tatano Y, Kashiwada Y.

Org Lett. 2016 Oct 21;18(20):5360-5363. Epub 2016 Sep 28.

PMID:
27682178
7.

[Unique macrophages induced by infection with Mycobacterium avium complex regulate the mitogenesis and differentiation of T cells].

Tatano Y, Tomioka H.

Seikagaku. 2016 Oct;88(5):660-3. Review. Japanese. No abstract available.

PMID:
29624338
8.

Erecricins A-E, prenylated acylphloroglucinols from the roots of Hypericum erectum.

Lu S, Tanaka N, Tatano Y, Kashiwada Y.

Fitoterapia. 2016 Oct;114:188-193. doi: 10.1016/j.fitote.2016.08.014. Epub 2016 Aug 26.

PMID:
27575327
9.

[M1 AND M2 MACROPHAGE POPULATIONS: THOSE INDUCED AND ACTIVATED BY MYCOBACTERIAL INFECTIONS].

Tomioka H, Tatano Y, Sano C, Shimizu T.

Kekkaku. 2016 Feb;91(2):75-82. Review. Japanese.

PMID:
27263230
10.

Aldose reductase participates in the downregulation of T cell functions due to suppressor macrophages.

Shimizu T, Tatano Y, Tomioka H.

Sci Rep. 2016 Feb 12;6:21093. doi: 10.1038/srep21093.

11.

ATP exhibits antimicrobial action by inhibiting bacterial utilization of ferric ions.

Tatano Y, Kanehiro Y, Sano C, Shimizu T, Tomioka H.

Sci Rep. 2015 Feb 25;5:8610. doi: 10.1038/srep08610.

12.

In vivo crystallography at X-ray free-electron lasers: the next generation of structural biology?

Gallat FX, Matsugaki N, Coussens NP, Yagi KJ, Boudes M, Higashi T, Tsuji D, Tatano Y, Suzuki M, Mizohata E, Tono K, Joti Y, Kameshima T, Park J, Song C, Hatsui T, Yabashi M, Nango E, Itoh K, Coulibaly F, Tobe S, Ramaswamy S, Stay B, Iwata S, Chavas LM.

Philos Trans R Soc Lond B Biol Sci. 2014 Jul 17;369(1647):20130497. doi: 10.1098/rstb.2013.0497.

13.

Unique macrophages different from M1/M2 macrophages inhibit T cell mitogenesis while upregulating Th17 polarization.

Tatano Y, Shimizu T, Tomioka H.

Sci Rep. 2014 Feb 20;4:4146. doi: 10.1038/srep04146.

14.

[Phagocytosis of Mycobacterium leprae down-regulates anti-microbial activity of murine macrophages against Mycobacterium intracellulare].

Tatano Y, Sano C, Emori M, Saito H, Sato K, Shimizu T, Tomioka H.

Nihon Hansenbyo Gakkai Zasshi. 2012 Sep;81(3):175-83. Japanese.

PMID:
23012845
15.

Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages.

Tomioka H, Tatano Y, Maw WW, Sano C, Kanehiro Y, Shimizu T.

Clin Dev Immunol. 2012;2012:635451. doi: 10.1155/2012/635451. Epub 2012 May 15. Review.

16.

Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.

Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H.

Int J Antimicrob Agents. 2011 Apr;37(4):296-301. doi: 10.1016/j.ijantimicag.2010.12.014. Epub 2011 Feb 25.

PMID:
21353489
17.

Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.

Tomioka H, Tatano Y, Sano C, Shimizu T.

J Infect Chemother. 2011 Jun;17(3):302-17. doi: 10.1007/s10156-010-0177-y. Epub 2011 Jan 18. Review.

PMID:
21243398
19.

In vitro drug susceptibility of Mycobacterium bovis BCG Connaught and Tokyo strains.

Shimizu T, Yasumoto K, Tatano Y, Tomioka H, Sato K, Sano C, Kumon H, Monden K.

J Infect. 2010 Mar;60(3):248-51. doi: 10.1016/j.jinf.2010.01.002. Epub 2010 Jan 13. No abstract available.

PMID:
20074586
20.

Recent advances in antituberculous drug development and novel drug targets.

Tomioka H, Tatano Y, Yasumoto K, Shimizu T.

Expert Rev Respir Med. 2008 Aug;2(4):455-71. doi: 10.1586/17476348.2.4.455.

PMID:
20477209

Supplemental Content

Loading ...
Support Center